{"product_id":"armidyn-anastrozole","title":"Armidyn (Anastrozole)","description":"\u003ch4\u003e\u003cspan class=\"\"\u003eAbout the Product\u003c\/span\u003e\u003c\/h4\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eArmidyn\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e is a research compound from Driada Medical, containing \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eAnastrozole\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e. Anastrozole is a potent, non-steroidal, and highly selective aromatase inhibitor \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020541s016lbl.pdf#6#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. Its chemical formula is C₁₇H₁₉N₅, with a molecular weight of 293.4 g\/mol and a CAS number of 120511-73-1 \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020541s016lbl.pdf#6#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.chemicalbook.cn\/ProductMSDSDetailCB3121715_EN.htm\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.drugfuture.com\/chemdata\/Anastrozole.html\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cspan class=\"\"\u003eThe compound functions by inhibiting the aromatase enzyme (cytochrome P450 19A1), which is responsible for the conversion of androgens (such as androstenedione and testosterone) to estrogens (estrone and estradiol) \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.benchchem.com\/pdf\/Application_Notes_Anastrozole_d12_for_In_Vitro_Aromatase_Inhibition_Studies.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. This mechanism makes it a valuable research tool for studying estrogen-dependent pathways.\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eProduct Name:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Armidyn (Anastrozole)\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eBrand:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Driada Medical\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eForm:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Solution for research applications\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eCAS:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e 120511-73-1\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eFor Research Use Only.\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch4\u003e\u003cspan class=\"\"\u003eResearch Applications \u0026amp; Mechanism of Action\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003ePotent Aromatase Inhibition:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Anastrozole is a benchmark compound for studying estrogen biosynthesis due to its high potency and selectivity \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020541s016lbl.pdf#6#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.benchchem.com\/pdf\/Application_Notes_Anastrozole_d12_for_In_Vitro_Aromatase_Inhibition_Studies.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. It acts as a \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003ecompetitive inhibitor\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e of the aromatase enzyme, with an IC₅₀ of approximately 9.4–15 nM in vitro \u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/pdf\/Application_Notes_Anastrozole_d12_for_In_Vitro_Aromatase_Inhibition_Studies.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. This high affinity allows researchers to effectively suppress estrogen production in experimental models.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eEstrogen Deprivation Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e As a tool to deplete estrogens, anastrozole is widely used to study hormone-dependent cellular processes, including gene regulation, cell proliferation, and apoptosis in various tissue types \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.benchchem.com\/pdf\/Application_Notes_Anastrozole_d12_for_In_Vitro_Aromatase_Inhibition_Studies.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eReceptor Biology \u0026amp; Endocrine Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Anastrozole's ability to lower estradiol without affecting adrenal corticosteroid synthesis makes it valuable for isolating the effects of estrogen from other endocrine pathways \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020541s016lbl.pdf#6#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eDrug Metabolism \u0026amp; CYP450 Studies:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Anastrozole is known to inhibit certain cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP3A) at high concentrations, making it relevant for drug-drug interaction research \u003c\/span\u003e\u003ca href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0090955624037711\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. These interactions occur at concentrations approximately 30 times higher than therapeutic levels, which is an important consideration for in vitro studies \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003ePharmacogenomics Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Genomic studies have identified genetic variants (such as SNPs in the \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eCSMD1\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e gene) that may influence individual responses to anastrozole \u003c\/span\u003e\u003ca href=\"https:\/\/mayoclinic.elsevierpure.com\/en\/publications\/pharmacogenomics-of-aromatase-inhibitors-in-postmenopausal-breast\/\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. This makes it a key compound for investigating the genetic basis of treatment response variability.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eCancer Research:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Anastrozole is a principal compound for studying hormone-sensitive cancers, particularly ER-positive breast cancer models, including research on mechanisms of resistance \u003c\/span\u003e\u003ca href=\"https:\/\/mayoclinic.elsevierpure.com\/en\/publications\/pharmacogenomics-of-aromatase-inhibitors-in-postmenopausal-breast\/\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/ouci.dntb.gov.ua\/en\/works\/98eJPKj7\/\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch4\u003e\u003cspan class=\"\"\u003eResearch \u0026amp; Scientific Background\u003c\/span\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eMechanism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Anastrozole's triazole ring binds reversibly to the heme iron in the aromatase enzyme's catalytic site, blocking the enzyme from converting androgens to estrogens \u003c\/span\u003e\u003ca href=\"https:\/\/www.benchchem.com\/pdf\/Application_Notes_Anastrozole_d12_for_In_Vitro_Aromatase_Inhibition_Studies.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. In postmenopausal research models, it reduces serum estradiol by approximately 70% within 24 hours and up to 80% after 14 days of dosing \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.benchchem.com\/pdf\/Application_Notes_Anastrozole_d12_for_In_Vitro_Aromatase_Inhibition_Studies.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eSelectivity:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Anastrozole is highly selective for aromatase and does not affect the formation of adrenal corticosteroids or aldosterone \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/020541s016lbl.pdf#6#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. It also does not possess direct progestogenic, androgenic, or estrogenic activity \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eMetabolism:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Anastrozole is primarily metabolized in the liver via N-dealkylation, hydroxylation, and glucuronidation by cytochrome P450 enzymes \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"http:\/\/www.bccancer.bc.ca\/NR\/rdonlyres\/257C9CFC-35D9-47B2-B5A5-FC7FF482077F\/52224\/FinalAnastrozolemonograph_14Jul2011.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. Its major metabolite, triazole, lacks pharmacological activity \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"http:\/\/www.bccancer.bc.ca\/NR\/rdonlyres\/257C9CFC-35D9-47B2-B5A5-FC7FF482077F\/52224\/FinalAnastrozolemonograph_14Jul2011.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. Approximately 85% of the compound is eliminated via hepatic metabolism, with about 10% excreted renally \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"http:\/\/www.bccancer.bc.ca\/NR\/rdonlyres\/257C9CFC-35D9-47B2-B5A5-FC7FF482077F\/52224\/FinalAnastrozolemonograph_14Jul2011.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003ePharmacokinetics:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Anastrozole is rapidly absorbed, reaching peak plasma concentrations within 2 hours \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"http:\/\/www.bccancer.bc.ca\/NR\/rdonlyres\/257C9CFC-35D9-47B2-B5A5-FC7FF482077F\/52224\/FinalAnastrozolemonograph_14Jul2011.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. It has a terminal elimination half-life of approximately \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003e50 hours\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e (range 30-60 h) \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"http:\/\/www.bccancer.bc.ca\/NR\/rdonlyres\/257C9CFC-35D9-47B2-B5A5-FC7FF482077F\/52224\/FinalAnastrozolemonograph_14Jul2011.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. Steady-state plasma levels are achieved after approximately 7 days of daily dosing and are 3- to 4-fold higher than after a single dose \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"http:\/\/www.bccancer.bc.ca\/NR\/rdonlyres\/257C9CFC-35D9-47B2-B5A5-FC7FF482077F\/52224\/FinalAnastrozolemonograph_14Jul2011.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. The compound is approximately 40% bound to plasma proteins \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"http:\/\/www.bccancer.bc.ca\/NR\/rdonlyres\/257C9CFC-35D9-47B2-B5A5-FC7FF482077F\/52224\/FinalAnastrozolemonograph_14Jul2011.pdf#1#1\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eGenetic Variability:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e Research has shown that inter-individual variability in response to anastrozole may be linked to genetic factors. A study identified that a SNP in the \u003c\/span\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eCSMD1\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e gene was associated with differential patient outcomes and that CSMD1 regulates CYP19 expression in a drug-dependent fashion, specifically affecting anastrozole sensitivity \u003c\/span\u003e\u003ca href=\"https:\/\/mayoclinic.elsevierpure.com\/en\/publications\/pharmacogenomics-of-aromatase-inhibitors-in-postmenopausal-breast\/\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. Additionally, polymorphisms in genes encoding UGT2B17 have been shown to influence the metabolism and detection of exogenous hormones like testosterone cypionate, highlighting the growing importance of pharmacogenomics in endocrine research. This suggests that genetic differences in drug-metabolizing enzymes and regulatory pathways may impact compound metabolism and response.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"ds-markdown-paragraph\"\u003e\u003cstrong\u003e\u003cspan class=\"\"\u003eDose-Response Studies:\u003c\/span\u003e\u003c\/strong\u003e\u003cspan class=\"\"\u003e In clinical research, doses of anastrozole from 0.5 mg to 10 mg have been evaluated for estrogen suppression \u003c\/span\u003e\u003ca href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/20541Org1s020.pdf#7#5\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003ca href=\"https:\/\/mayoclinic.elsevierpure.com\/en\/publications\/anastrozole-dose-escalation-for-optimal-estrogen-suppression-in-p\/\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. Recent studies indicate that approximately 30% of individuals on standard 1 mg\/day dosing may achieve inadequate estrogen suppression, and dose escalation to 10 mg\/day can help achieve adequate suppression in about 76% of those cases \u003c\/span\u003e\u003ca href=\"https:\/\/mayoclinic.elsevierpure.com\/en\/publications\/anastrozole-dose-escalation-for-optimal-estrogen-suppression-in-p\/\" rel=\"noreferrer\" style=\"cursor: default;\" target=\"_blank\"\u003e\u003c\/a\u003e\u003cspan class=\"\"\u003e. This highlights the importance of dosing optimization in research models.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Driada","offers":[{"title":"Default Title","offer_id":58726459277637,"sku":null,"price":25.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1077\/7614\/7781\/files\/Driada-Armidyn.jpg?v=1785450148","url":"https:\/\/genetic-peps.shop\/products\/armidyn-anastrozole","provider":"Genetic Peps","version":"1.0","type":"link"}